BioCentury | Dec 1, 2020
Emerging Company Profile

Spotlight: solving CRISPR’s delivery challenges with RNPs

Spotlight emerged from stealth on Monday with a $30 million series A round led by GV and a platform that could help address the challenge of systemically delivering CRISPR-based gene editing therapies...
BioCentury | Dec 1, 2020
Product Development

Moderna moves & Immunocore breaks through: a BioCentury podcast

After its latest readout positioned the company to seek FDA authorization of its COVID-19 vaccine, Moderna has begun to look ahead to unblinding the Phase III trial of mRNA-1273 so participants who received a placebo can be...
BioCentury | Dec 1, 2020
Product Development

Nov. 30 Quick Takes: Grail piloting blood test in U.K.; plus Rhythm, Kadmon, venture rounds for Adrenomed, Xbiome, Transition

Grail piloting cancer blood test with NHS EnglandGrail Inc. announced a pilot program with NHS England using the company's Galleri blood test to monitor 140,000 asymptomatic participants aged 50 to 79 for three years, and...
BioCentury | Nov 26, 2020
Product Development

U.S. government spending on Abbott BinaxNOW outstrips other rapid COVID-19 tests: Data Byte

Abbott’s BinaxNOW test has replaced its predecessor as the Trump Administration’s favorite COVID-19 test. A fact sheet released by HHS Tuesday showed the U.S. federal government has spent $760 million on the antigen test from Abbott...
BioCentury | Nov 25, 2020
Product Development

Russia to launch Sputnik V vaccine into global orbit

The Russian government plans to exploit the low manufacturing cost and ease of storing and transporting its Sputnik V vaccine to engage in vaccine diplomacy, filling a gap left by the Trump administration’s America First...
BioCentury | Nov 25, 2020
Product Development

Steady stream of Phase III COVID-19 vaccine data to flow into the new year

The dizzying pace of COVID-19 vaccine readouts over the last three weeks is only going to accelerate over the next five. By the end of the year, three of the four leading vaccines are likely...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Nov 24, 2020
Management Tracks

ASCO names Gralow new CMO; plus moves at Genenta, Vor, Exscientia, OncoMyx, Quanterix, Actinium, AbCellera and KBP

The American Society of Clinical Oncology named Julie Gralow CMO, effective Feb. 15, 2021. Gralow, a professor of medical oncology and director of breast medical oncology at the University of Washington, Fred Hutchinson Cancer Research...
BioCentury | Nov 24, 2020
Product Development

Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime

NIH panel says bamlanivimab should not be considered standard-of-care for COVID-19NIH’s COVID-19 Treatment Guidelines Panel said there is not enough data to recommend either for or against use of bamlanivimab from Eli Lilly and Co. (NYSE:LLY)...
BioCentury | Nov 24, 2020
Deals

OncoImmune's choice to repurpose GvHD program for COVID pays off via $425M takeout by Merck

OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid off via a takeout by Merck for $425 million up front. Under the deal, which includes undisclosed milestones and royalties, Merck & Co. Inc....
Items per page:
1 - 10 of 28992